Virginia
Requires Coverage of Comprehensive Biomarker Testing
No
Highlighted Disparity
Asian or Pacific Islander individuals in Virginia are least likely to be diagnosed early
Lung Cancer Rates
New Cases:
- The rate of new lung cancer cases in Virginia is 50.4 and significantly lower than the national rate of 52.1.
- It ranks 17th among all states, placing it in the average tier.
- Over the last five years, the rate of new cases in Virginia improved by 11%.
- Note: When examining incidence data, it is important to note that the COVID-19 pandemic disrupted access to medical care. This resulted in a drop in cancer diagnoses for the year 2020, particularly for cancers diagnosed before symptoms develop (including lung cancer). This drop reflects changes in medical care for 2020 and should not necessarily be interpreted as a reduction in the underlying cancer burden.
Five-Year Survival Rate:
- The percent of people living five years after being diagnosed with lung cancer (the survival rate) is 31.0% nationally.
- Virginia is one of the 8 states for which survival data is not available.
Early Diagnosis:
- In Virginia, 29.7% of cases are caught at an early stage, which is not significantly different than the national rate of 29.3%.
- It ranks 24th among the 47 states with data on diagnosis at an early stage, placing it in the average tier.
- Over the last five years, the early diagnosis rate in Virginia improved by 31%.
Lung Cancer Treatment
Surgical Treatment:
- Virginia ranked 20th (out of the 40 states with available data) with 20.4% of cases undergoing surgery as part of the first course of treatment.
- This is significantly lower than the national rate of 21.4% and puts Virginia in the average tier.
Biomarker Coverage:
- Virginia has yet to require any insurance coverage of comprehensive biomarker testing, including for lung cancer, as of September 2026.
No Treatment:
- Virginia ranked 5th (out of the 47 states with available data) with 16.0% of cases not receiving any treatment.
- This is significantly lower than the national rate of 20.9% and puts Virginia in the top tier.
Screening
Screening for High Risk:
- In Virginia, 25.0% of those at high risk were screened, which was not significantly different than the national rate of 24.4%.
- It ranks 23rd (out of the 50 states with available data), placing it in the average tier.
Prevention
Tobacco Use:
- The 2025 smoking rate in Virginia is 10.1% and not significantly different than the national rate of 10.4%.
- It ranks 23rd (out of the 48 states with available data), placing it in the average tier.
Radon:
- In Virginia, 25.2% of radon tests results were at or above the action level recommended by EPA.
- It ranks 28th among all states, placing it in the average tier.
Racial & Ethnic Disparities
Black individuals:
- The rate of new lung cancer cases is 53.1 per 100,000 population among Black individuals in Virginia, not significantly different than the rate of 53.5 among Black individuals nationally, and not significantly different than the rate of 53.0 among white individuals in Virginia.
- Survival rates by race and ethnicity are not available for Virginia at this time. Nationally, the five-year survival rate among Black individuals is 28.5%, 8% lower than among white Americans.
25.7% of lung cancer cases are diagnosed at an early stage among Black individuals in Virginia, not significantly different than the rate of 26.3% among Black individuals nationally, and significantly lower than the rate of 31.0% among white individuals in Virginia.
18.2% of Black individuals with lung cancer in Virginia underwent surgery, not significantly different than the rate of 17.9% among Black individuals nationally, and significantly lower than the rate of 20.7% among white individuals in Virginia.
16.5% of Black individuals with lung cancer in Virginia did not receive any treatment, significantly lower than the rate of 22.7% among Black individuals nationally, and not significantly different than the rate of 16.0% among white individuals in Virginia.
Latino individuals:
- The rate of new lung cancer cases is 19.8 per 100,000 population among Latino individuals in Virginia, significantly lower than the rate of 27.8 among Latino individuals nationally, and significantly lower than the rate of 53.0 among white individuals in Virginia.
- State-level survival rates are not available for Latino individuals at this time. Nationally, the five-year survival rate among Latino individuals is 22.7%, not significantly different than the rate of 25.0% among white individuals.
27.5% of lung cancer cases are diagnosed at an early stage among Latino individuals in Virginia, not significantly different than the rate of 24.7% among Latino individuals nationally, and not significantly different than the rate of 31.0% among white individuals in Virginia.
24.2% of Latino individuals with lung cancer in Virginia underwent surgery, not significantly different than the rate of 22.0% among Latino individuals nationally, and not significantly different than the rate of 20.7% among white individuals in Virginia.
16.3% of Latino individuals with lung cancer in Virginia did not receive any treatment, significantly lower than the rate of 25.1% among Latino individuals nationally, and not significantly different than the rate of 16.0% among white individuals in Virginia.
Asian or Pacific Islander individuals:
- The rate of new lung cancer cases is 27.9 per 100,000 population among Asian or Pacific Islanders individuals in Virginia, significantly lower than the rate of 32.7 among Asian or Pacific Islanders individuals nationally, and significantly lower than the rate of 53.0 among white individuals in Virginia.
- State-level survival rates are not available for Asian or Pacific Islander individuals at this time. Nationally, the five-year survival rate among Asian or Pacific Islander individuals is 28.6% and significantly higher than the rate of 25.0% among white individuals.
24.2% of lung cancer cases are diagnosed at an early stage among Asian or Pacific Islander individuals in Virginia, not significantly different than the rate of 24.8% among Asian or Pacific Islander individuals nationally, and significantly lower than the rate of 31.0% among white individuals in Virginia.
23.3% of Asian or Pacific Islander individuals with lung cancer in Virginia underwent surgery, not significantly different than the rate of 26.0% among Asian or Pacific Islander individuals nationally, and not significantly different than the rate of 20.7% among white individuals in Virginia.
14.4% of Asian or Pacific Islander individuals with lung cancer in Virginia did not receive any treatment, significantly lower than the rate of 19.1% among Asian or Pacific Islander individuals nationally, and not significantly different than the rate of 16.0% among white individuals in Virginia.
Indigenous Peoples:
- The rate of new lung cancer cases is 26.1 per 100,000 population among Indigenous peoples (American Indians/Alaska Natives) in Virginia, significantly lower than the rate of 38.0 among Indigenous Peoples nationally, and significantly lower than the rate of 53.0 among white individuals in Virginia.
- State-level survival rates are not available for Indigenous Peoples at this time. Nationally, the five-year survival rate among Indigenous Peoples is 22.3% and not significantly different than the rate of 25.0% among white individuals.
Lung cancer data (including early diagnosis, surgery, lack of treatment) is incomplete or unavailable for Indigenous Peoples (American Indians/Alaska Natives) in Virginia due to data limitations.
Summary
Despite the early diagnosis rate in Virginia falling into the average tier, the state still has a lot of work to do to make sure that more of those at high risk for lung cancer are screened.
Virginia has yet to require any insurance coverage of comprehensive biomarker testing, which can help determine what treatment options would be best for individuals with lung cancer and other diseases.
Virginia falls into the top tier for percent of patients receiving no treatment. Some patients do refuse treatment, but issues such as fatalism and stigma can prevent eligible patients from accessing treatment that may save or extend their lives. All patients should work with their doctors to establish a treatment plan and goals.
Page last updated: November 10, 2026